Patent Ductus Arteriosus Stenting in Infants with Duct-Dependent Pulmonary Circulation: An Indian Experience

Deepali Bangalia1, Hemanta Nayak1, Sudipta Bhattacharjya1

  • 1Pediatric Cardiology Department, The Mission Hospital Durgapur, Durgapur, India.

Cardiology
|April 30, 2026
PubMed

Insights

Patent ductus arteriosus (PDA) stenting using drug-eluting coronary stents is a safe and effective palliative strategy for neonates with duct-dependent pulmonary circulation, improving procedural and follow-up outcomes.

Area of Science:

  • Pediatric Cardiology
  • Interventional Cardiology
  • Neonatology

Background:

  • Patent ductus arteriosus (PDA) is a critical condition in neonates with duct-dependent pulmonary circulation.
  • Timely intervention is crucial for managing these complex congenital heart defects.

Purpose of the Study:

  • To evaluate the outcomes of PDA stenting using the latest generation drug-eluting coronary stents.
  • To assess the safety and efficacy of this strategy in neonates with duct-dependent pulmonary circulation.

Main Methods:

  • Retrospective, observational study including 58 infants with duct-dependent pulmonary circulation.
  • PDA stenting performed using drug-eluting coronary stents.
  • Follow-up for up to 12 months post-procedure.

Main Results:

  • Successful stent deployment in 100% of patients.
  • Low in-hospital mortality (6.9%) and 12-month mortality (reported deaths up to 12 months).
  • 19 patients underwent univentricular repair, 4 underwent biventricular repair within 12 months.

Conclusions:

  • PDA stenting with latest-generation drug-eluting coronary stents is a safe and effective palliative strategy.
  • This approach offers improved procedural and follow-up outcomes for neonates with duct-dependent pulmonary circulation.
Abstract

Related Concept Videos